Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for Beijing Airdoc Technology Co's PEG Ratio or its related term are showing as below:
HKSE:02251's PEG Ratio is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 1.46 * Ranked among companies with meaningful PEG Ratio only.
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
Beijing Airdoc Technology Co (HKSE:02251) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
Beijing Airdoc Technology Co PEG Ratio Related Terms
Beijing Airdoc Technology Co PEG Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:02251 vs VEEV, BTSG, TEM: PEG Ratio Comparison
For the Health Information Services subindustry, Beijing Airdoc Technology Co's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beijing Airdoc Technology Co PEG Ratio vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Beijing Airdoc Technology Co's PEG Ratio distribution charts can be found below:
* The bar in red indicates where Beijing Airdoc Technology Co's PEG Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
Beijing Airdoc Technology Co (HKSE:02251) has a PEG Ratio of 0.00 as of Sep. 03, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Beijing Airdoc Technology Co and its competitors. According to the industry distribution chart, Beijing Airdoc Technology Co ranks #999999 out of 225 companies in the Healthcare Providers & Services industry.
Is Beijing Airdoc Technology Co's PEG Ratio too high?
Beijing Airdoc Technology Co's current PEG Ratio is 0.00. Based on the distribution chart, Beijing Airdoc Technology Co ranks #999999 out of 225 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Beijing Airdoc Technology Co has a GF Score™ of 64/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Beijing Airdoc Technology Co's PEG Ratio compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Beijing Airdoc Technology Co ranks #999999 out of 225 companies for PEG Ratio. This places Beijing Airdoc Technology Co in the lower half of its industry. The industry median PEG Ratio is 1.46. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Healthcare Providers & Services company?
The median PEG Ratio among Healthcare Providers & Services companies is 1.46, based on 225 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Beijing Airdoc Technology Co and its competitors. For the Healthcare Providers & Services industry, the median PEG Ratio is 1.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Beijing Airdoc Technology Co's current PEG Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beijing Airdoc Technology Co stock overvalued right now?
Based on GuruFocus' analysis, Beijing Airdoc Technology Co (HKSE:02251) is currently considered Significantly Undervalued. The stock's GF Value™ is HK$15.18, compared to a current price of HK$7.91 — trading 47.9% below its estimated fair value. The current PEG Ratio is 0.00. Beijing Airdoc Technology Co's overall GF Score™ is 64/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For Beijing Airdoc Technology Co (HKSE:02251), the current PEG Ratio is 0.00 as of Sep. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Beijing Airdoc Technology Co (HKSE:02251) Overvalued in 2026?
Based on GuruFocus' analysis, Beijing Airdoc Technology Co stock appears to be undervalued.
The current stock price of HK$7.91 is trading 47.9% below its estimated GF Value™ of HK$15.18.
GuruFocus considers Beijing Airdoc Technology Co to be Significantly Undervalued.
Key valuation signals for HKSE:02251:
PEG Ratio: 0.00
GF Value™: HK$15.18 vs. price of HK$7.91 (47.9% below fair value)
No single metric tells the full story. See the HKSE:02251 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Beijing Airdoc Technology Co Ltd provides AI-empowered retina-based early detection, diagnosis, and health risk assessment solutions in China. Leveraging retinal imaging, multimodal data analyses, and AI deep learning algorithms, the company's solution differs from traditional chronic disease early detection and diagnosis, enabling non-invasive, accurate, fast, effective, and scalable detection and diagnosis of chronic diseases in both medical institutions and consumer healthcare providers. The Company derives revenue from the provision of AI-based software solutions, sales of hardware devices, and other services. Geographically, the company generates the majority of its revenue from Mainland China.
64GF Score
Get the complete analysis for HKSE:02251
PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02251 has been successfully added to your 
